Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVRd followed by cilta-cel versus DVRd followed by ASCT in newly diagnosed multiple myeloma
NL-OMON60538Phase 3Recruiting
- Sponsor
- European Myeloma Network B.V.
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ciltacabtagene autoleucel, daratumumab, bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by European Myeloma Network B.V. Primary endpoints: Progression-free survival and Sustained MRD-negative complete response. Started May 2024; status: recruiting.
02
Drugs
ciltacabtagene autoleuceldaratumumabbortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON60538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60538.